Home
Diseases
Neuroendocrine Tumors

Neuroendocrine Tumors

Disease

Related News

CT-Based Biomarker Improves Gastric Cancer Prognosis; PET Imaging Market Grows; Neuroendocrine Tumor Research Advances

Jun 24, 2026

Brazilian researchers developed a CT-based biomarker called VMD that combines visceral fat and muscle radiodensity to predict gastric cancer prognosis, with patient survival ranging from 13.8 to 58.5 months. The global PET imaging market is projected to grow to $1.4 billion by 2032 as cancer cases rise globally. Neuroendocrine tumor research is advancing with new funding and studies on Hedgehog signaling pathways.

Global Oncology and Radiopharmaceuticals Markets Poised for Strong Growth Through 2035

Jun 11, 2026

The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.

Radioligand Therapeutics Market Seen Growing to $4.8 Billion by 2030

May 04, 2026

The radioligand therapeutics market in cancer treatment is estimated to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at a 13.1% CAGR. Growth is supported by approved products Pluvicto and Lutathera and expanding use of PSMA and SSTR-targeted therapies.

Novartis pipeline and growth targets remain central to investor focus

Apr 18, 2026

Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.

Cabozantinib studies in advanced neuroendocrine tumors show efficacy signal and mixed cost-effectiveness

Apr 11, 2026

Cabozantinib plus metronomic temozolomide showed a 15% response rate and 28.5-month median progression-free survival in a phase 2 NET study. A separate analysis found cabozantinib cost-effective for pancreatic NETs, but not extrapancreatic NETs, in China and the U.S.

Radioligand Therapy Market Poised for Major Growth Through 2030

Mar 12, 2026

The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.

CAR T-Cell Therapy Advances Target Solid Tumors and Selective Cancer Killing

Feb 14, 2026

Researchers have developed modified CAR T cells that overcome prostaglandin E2 suppression in solid tumors and a selective therapy targeting IGHV4-34 that spares healthy immune cells, addressing key limitations in current treatments.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07534371	Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study	ACTIVE_NOT_RECRUITING
NCT07450287	CardioNETPOL National Registry of Carcinoid Heart Disease	NOT_YET_RECRUITING
NCT07404176	Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors	RECRUITING	PHASE2
NCT07369505	Sapu003 in Advanced mTOR-sensitive Solid Tumors	RECRUITING	PHASE1
NCT07366658	Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients	NOT_YET_RECRUITING	PHASE1
NCT07314164	Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment	RECRUITING
NCT07272512	Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms	RECRUITING	PHASE4
NCT07165132	Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.	RECRUITING	PHASE1
NCT07151391	The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)	RECRUITING	PHASE2
NCT07129252	A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors	RECRUITING	PHASE1/PHASE2